Markets

Medicenna Therapeutics Appoints Nageatte Ibrahim As CMO

April 09, 2026 — 08:09 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Medicenna Therapeutics Corp. (MDNAF.PK), Thursday announced the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer of the company.

Previously, Dr. Ibrahim served as Chief Medical Officer of Oncology at Innovent Biologics USA, where she established and led a global clinical development organization and played a key role in building the company's U.S. presence.

Commenting on the appointment, Dr. Ibrahim said, "The company's IL-2 superagonist programs, MDNA11 and MDNA113, hold promise to improve outcomes for patients with various solid tumors with bizaxofusp (MDNA55) demonstrating compelling evidence of efficacy in patients with glioblastoma, one of the most challenging cancers with significant unmet needs. I look forward to working with the team to accelerate the clinical development of these therapies."

MDNAF closed trading at $0.46, up 4.31 percent on the OTC Markets.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned

Latest Articles
Data is currently not available